Compare Repligen Corporation Common Stock (RGEN) vs Smurfit WestRock plc Ordinary Shares (SW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Smurfit WestRock plc Ordinary Shares — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Smurfit WestRock plc Ordinary Shares trades at $40.75 (market cap $21.74B). The key difference: Smurfit WestRock plc Ordinary Shares is the larger of the two by market cap, and Smurfit WestRock plc Ordinary Shares pays a 4.36% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Smurfit WestRock plc Ordinary Shares for 5 Days on average.
| RGEN | SW | |
|---|---|---|
Market Cap | $11.14B | $21.74B |
Volume | 1,259,263 | 2,458,317 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $51.84 |
52-Week Low | $102.87 | $32.79 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $11.02B | $35.23B |
Dividend Yield | — | 4.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Smurfit Westrock (SW) trades at $41.45, showing modest daily gains of 0.93% but facing technical bearish signals with 17 sell indicators versus 4 buys. The company reported three consecutive quarterly earnings misses amid cost pressures, though revenue remains stable above $31 billion. Recent strategic moves include the $420 million acquisition of CMPC's Chilean containerboard business to strengthen regional footprint and reduce costs.
Despite unanimous analyst buy ratings and a $71.50 price target suggesting 72% upside, SW faces execution risks from freight cost inflation and margin compression. The stock's high P/E ratio of 44.01 contrasts with weak profitability metrics (ROE 2.74%), creating a divergence between valuation and fundamental performance that warrants cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Smurfit WestRock plc Ordinary Shares
Smurfit WestRock plc is an Ireland-headquartered packaging company that manufactures corrugated containers and consumer packaging from containerboard and paperboard, operating mills, converting plants, and recycling facilities across more than 40 countries.
Read more on SW →
